Table 3.
Study Eyes | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Type of | Type 1 | Type 2 | OCTA | Vascular | OCTA | |||||
Author | Year | Diabetes | Total | DM | DM | Controls | Parameter | Plexus | Device | Software |
Carnevali et al.24 | 2017 | 1 | 50 | 25 | – | 25 | VD, FAZ | S, D, CC | Cirrus Angioplex | Custom - Image J |
Sacconi et al.25 | 2019 | 1 | 61 | 34 | – | 27 | PD, FAZ | S, D, CC | PLEX Elite 9000 | Built in |
Li et al.26 | 2019 | 1 | 91 | 47 (children) | – | 44 | VD, PD, FAZ | S | Cirrus Angioplex | Built in |
Mameli et al.29 | 2019 | 1 | 94 | 53 (children) | – | 41 | VD | S, D | RTVue XR Avanti | Built in |
Inanc et al.30 | 2019 | 1 | 117 | 60 (children) | – | 57 | VD, PD, FAZ | S, D | RTVue XR Avanti | Built in |
Niestrata-Ortiz et al.28 | 2019 | 1 | 142 | 112 (children) | – | 30 | FAZ | S, D | DRI OCT-A Triton | Built in |
Golebiewska et al.27 | 2017 | 1 | 248 | 188 (children) | – | 60 | VD, FAZ | S, D | RTVue XR Avanti | Built in |
Dimitrova et al.34 | 2017 | Both | 62 | ? | 29 | 33 | VD, FAZ | S, D, CC | RTVue XR Avanti | Built in |
Lupidi et al.11 | 2017 | Both | 95 | ? | 48 | 47 | VD, PD, FAZ | S, D | Spectralis OCT2 | Built in |
Gozlan et al.23 | 2017 | Both | 58 | 9 | 49 | - | PD, FAZ, | S, D | RTVue XR Avanti | Built in |
De Carlo et al.35 | 2015 | Both | 82 | ? | 61 | 21 | MA, PD, FAZ | Undisclosed | RTVue XR Avanti | Built in |
Vujosevic et al.16 | 2018 | Both | 117 | ? | 83 | 34 | VD, PD | S | DRI OCT-A Triton Plus | Custom - Image J |
Vujosevic et al.21 | 2019 | Both | 111 | 38 | 55 | 18 | VD, PD, FAZ | S, D | DRI OCT-A Triton | Custom - Image J |
Rodrigues et al.22 | 2019 | Both | 101 | 18 | 83 | - | VD, FAZ | S, D, CC | Angiovue System | Built in |
Choi et al.12 | 2017 | Both | 152 | ? | 89 | 63 | VD, FAZ | S, M, D, CC | UHS-SSOCT (MIT, NEEC) | Research prototype |
Rosen et al.17 | 2019 | Both | 153 | 9 | 104 | 40 | PD, FAZ | S, D | RTVue XR Avanti | Built in |
Nesper et al.37 | 2017 | Both | 181 | ? | 137 | 44 | VD, PD, FAZ | S, D, CC | RTVue XR Avanti | Built in |
Tang et al.13 | 2017 | Both | 434 | ? | 434 | – | VD, FD, FAZ | S | DRI OCT-A Triton | Built in |
Tang et al.41 | 2019 | Both | 447 | ? | 447 | – | VD, FAZ | S | DRI OCT-A Triton | Custom - MatLab |
Ishibazawa et al.4 | 2015 | Undisclosed | 47 | ? | 47 | – | MA, PD | S, D | RTVue XR Avanti | Built in |
Shen et al.18 | 2018 | Undisclosed | 90 | ? | 49 | 41 | VD | S | RTVue XR Avanti | Built in |
Samara et al.42 | 2017 | Undisclosed | 118 | ? | 84 | 34 | VD, FAZ | S, D | RTVue XR Avanti | Built in |
Mastropasqua et al.19 | 2019 | Undisclosed | 119 | ? | 94 | 25 | VD, PD | S, D, CC | PLEX Elite 9000 | Built in |
Conti et al.14 | 2018 | Undisclosed | 136 | ? | 99 | 37 | PD, FAZ | S, D, CC | RTVue XR Avanti | Built in |
Onishi et al.15 | 2018 | Undisclosed | 180 | ? | 136 | 44 | VD, PD | S, M, D | RTVue XR Avanti | Built in |
Yang et al.20 | 2019 | Undisclosed | 282 | ? | 239 | 43 | VD | CC | RTVue XR Avanti | Built in |
Cao et al.7 | 2018 | 2 | 138 | – | 71 | 67 | VD, PD, FAZ | S, D, CC | RTVue XR Avanti | Built in |
Ting et al.8 | 2017 | 2 | 100 | – | 100 | 0 | VD, FD | S, D | DRI OCT-A Triton | Built in |
Tan et al.43 | 2019 | 2 | 212 | – | 126 | 86 | VD | S, D | RTVue XR Avanti | Built in |
Zeng et al.9 | 2019 | 2 | 170 | – | 137 | 33 | VD | S, D | RTVue XR Avanti | Built in |
Kim et al.10 | 2018 | 2 | 155 | – | 155 | 0 | VD, PD, FAZ | S, D | Cirrus Angioplex | Custom - Image J |
This study | 2020 | 1 | 1186 | 956 | – | 230 | VD, PD, FAZ | S | CirrusAngioplex | Built in |
OCTA, optical coherence tomography angiography; DM, diabetes mellitus; VD, vessel density; PD, perfusion density; FAZ, foveal avascular zone; S, superficial; M, medium; D, deep; CC, choriocapillaris; RS, research software.
Note: The OCTA parameters may not have been described in the original papers exactly as those described in the table, as the terms have been unified for comparison purposes. Devices: Cirrus Angioplex, Carl Zeiss Meditec, Dublin, CA; PLEX Elite 9000, Carl Zeiss Meditec, Inc., Dublin, CA; RTVue XR Avanti, Optovue, Inc., Fremont, CA; Angiovue System, Optovue Inc., Fremont, CA; DRI OCT-A Triton Plus, Topcon Europe, Milano; Spectralis OCT2, Heidelberg Engineering, Heidelberg. (*= see “References” section).